Your session is about to expire
← Back to Search
Monoclonal Antibodies
Pre-PDT for Visual Acuity
Phase 4
Waitlist Available
Led By John Galic, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
The purpose of the investigators study is to look at the visual outcomes of Ranibizumab injections in combination with photodynamic therapy for the treatment of neovascular age-related macular degeneration.
Eligible Conditions
- Visual Acuity
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
3Treatment groups
Active Control
Group I: Pre-PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
Group II: No PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
Group III: Post-PDTActive Control1 Intervention
Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
461 Previous Clinical Trials
164,173 Total Patients Enrolled
John Galic, MDPrincipal InvestigatorMontreal Retina Institute
John Chen, MDPrincipal InvestigatorMontreal Retina Institute
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger